Latest Articlesddd
Prohost Letter #379 Investors Concerns, Excitments and Expectations It is understandable the fact that bullish and …
After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer …
Today it is Greece. What About Tomorrow? Can Greece’s crisis devastate the biotech sector? No sane …
On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website …
Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The …
– Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. – The firm …
VASCULAR BIOGENICS OPERATING AS VBL THERAPEUTICS Vascular Biogenics Ltd., operating as VBL Therapeutics (VBLT) is a …
Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab …
Prohost Letter #378 Part 1 Views and Visions TOP-TIER BIOTECHNOLOGY COMPANIES GILEAD We wrote a lot …
For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that …
AS WE AND PREDICTED, the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC), voted in favor of approving …
The FDA Advisory Committee Voted 22-1 In Favor of Approval of Its Melanoma Immunotherapy T-VEC Yesterday’s …
Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small …
As you would observe when reading the most recent Prohost Letters, our recent enthusiasm for Celldex …
Prohost Letter #376 WHILE LOOKING AT THE BIOTECHS SCIENTIFIC FUNDAMENTALS We keep an eye on other …
Exelixis Announces Acceptance of New Drug Application for Cobimetinib (NDA) in Combination with Vemurafenib for Treatment …
AERIE PHARMACEUTICALS (AERI) A YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE MARKET – Aerie Pharmaceuticals …
They jumped to call the biotech sector a bubble, accentuating its volatility. Instead of saying WOW …
Prohost Letter #375 Part 2 Novel Breakthrough Cancer Immunotherapy Approaches PART 2 In Part 1 of this …
Prohost Letter #375 Part 1 BIOTECHNOLOGY: THE BEGINNING OF A NEW ERA STATE- OF-THE-ART APPROACHES FOR THE …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
